Cinclus Pharma Holding AB (OSTO:CINPHA) Other Financing: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CINPHA Cinclus Pharma Holding AB OSTO:CINPHA
6 GF Score
Price kr11.94
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Other Financing?

Cinclus Pharma Holding AB OSTO:CINPHA -2.61% 6 Other Financing is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:CINPHA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Other Financing for the three months ended in Mar. 2026 was kr0.00 Mil.

Cinclus Pharma Holding AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Cinclus Pharma Holding AB Other Financing Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Other Financing Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
-0.13 -15.42 -0.17 -58.42 0.00

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:CINPHA
6GF Score
Cinclus Pharma Holding AB OSTO:CINPHA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr0.00 Mil mean?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a Other Financing of kr0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Other Financing too high?
Cinclus Pharma Holding AB's current Other Financing is kr0.00 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Other Financing compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Other Financing of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Other Financing is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a current Other Financing of kr0.00 Mil. The current Other Financing is kr0.00 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cinclus Pharma Holding AB (OSTO:CINPHA), the current Other Financing is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for OSTO:CINPHA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.94
Price